CLEVELAND, May 12, 2023 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (NASDAQ: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced that Chairman and CEO Michael B. Petras, Jr. will participate in an open forum discussion at the 2023 RBC Capital Markets Global Healthcare Conference on Tuesday, May 16, 2023 at 4:35 pm Eastern. Sotera Health management will also participate in one-on-one meetings with investors during the conference.
Investors and the general public are invited to listen to the live webcast of Mr. Petras’ discussion by accessing the link on the Sotera Health website under the Investor Relations section: https://investors.soterahealth.com/events-and-presentations. A replay will also be made available.
About Sotera Health:
Sotera Health Company is a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry. Sotera Health goes to market through three businesses – Sterigenics®, Nordion® and Nelson Labs®. Sotera Health is committed to its mission, Safeguarding Global Health®.
INVESTOR RELATIONS CONTACTS: | ||
Jason Peterson Vice President & Treasurer Sotera Health Company This email address is being protected from spambots. You need JavaScript enabled to view it. | Sally J. Curley, IRC IR Advisory Solutions This email address is being protected from spambots. You need JavaScript enabled to view it. | |
MEDIA CONTACT: | ||
Kristin Gibbs Chief Marketing Officer Sotera Health Company This email address is being protected from spambots. You need JavaScript enabled to view it. | ||
Last Trade: | US$13.21 |
Daily Change: | -0.40 -2.94 |
Daily Volume: | 2,407,179 |
Market Cap: | US$3.740B |
November 05, 2024 September 04, 2024 August 05, 2024 May 30, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB